Immune approaches in myeloma and plasma cell targets
| Target . | Antibody . | Current status . |
|---|---|---|
| Cell surface targets | ||
| CD38 | Daratumumab | Effective as single agent, in combination with IMiDs and PIs, approved for clinical use |
| Isatuximab | In clinical trials, effective as single agent, in combination with IMiDs | |
| MOR202 | In clinical trials | |
| SLAMF7 | Elotuzumab | Effective in combination with IMiDs and PIs, approved for clinical use |
| CD138 | Indatuximab ravtansine (BT062) | In clinical trials for myeloma, as single agent overall response was 4%, in combination with Len ORR was 78% |
| CD56 | Lorvotuzumab | Response rate of 7% single agent and 56% with Len-Dex, in clinical trials for myeloma |
| CD40 | Dacetuzumab (SGN40) and lucatumumab | In clinical trials for myeloma, no responses with single agents |
| CD74 | Milatuzumab (hLL1) | In phase 1 trial, no objective responses. Combination trials ongoing |
| Cytokine/growth factor targeted | ||
| IL-6 | Siltuximab | No clinical efficacy in MM, approved for treatment of Castleman disease |
| VEGF | Avastin | No clinical efficacy in MM |
| BAFF | Tabalumab (LY2127399) | In a phase 1 study in relapsed MM, combination with Bort-Dex had an ORR of 46% |
| DKK1 | BHQ880 | Bone beneficial effects seen in early trials |
| CXCR4 | Ulocuplumab | ORR was 55% in combination with Len-Dex and 40% with Btz-Dex |
| T-cell approaches | ||
| CD19 | CART | In early-phase trials, CRs noted |
| BCMA | CART | In early-phase clinical trials, CRs noted |
| BCMA | BiTE | Entering clinical trials |
| Target . | Antibody . | Current status . |
|---|---|---|
| Cell surface targets | ||
| CD38 | Daratumumab | Effective as single agent, in combination with IMiDs and PIs, approved for clinical use |
| Isatuximab | In clinical trials, effective as single agent, in combination with IMiDs | |
| MOR202 | In clinical trials | |
| SLAMF7 | Elotuzumab | Effective in combination with IMiDs and PIs, approved for clinical use |
| CD138 | Indatuximab ravtansine (BT062) | In clinical trials for myeloma, as single agent overall response was 4%, in combination with Len ORR was 78% |
| CD56 | Lorvotuzumab | Response rate of 7% single agent and 56% with Len-Dex, in clinical trials for myeloma |
| CD40 | Dacetuzumab (SGN40) and lucatumumab | In clinical trials for myeloma, no responses with single agents |
| CD74 | Milatuzumab (hLL1) | In phase 1 trial, no objective responses. Combination trials ongoing |
| Cytokine/growth factor targeted | ||
| IL-6 | Siltuximab | No clinical efficacy in MM, approved for treatment of Castleman disease |
| VEGF | Avastin | No clinical efficacy in MM |
| BAFF | Tabalumab (LY2127399) | In a phase 1 study in relapsed MM, combination with Bort-Dex had an ORR of 46% |
| DKK1 | BHQ880 | Bone beneficial effects seen in early trials |
| CXCR4 | Ulocuplumab | ORR was 55% in combination with Len-Dex and 40% with Btz-Dex |
| T-cell approaches | ||
| CD19 | CART | In early-phase trials, CRs noted |
| BCMA | CART | In early-phase clinical trials, CRs noted |
| BCMA | BiTE | Entering clinical trials |
BAFF, B-cell activating factor; BiTE, bispecific T-cell engager; Bort, bortezomib; IL-6, interleukin 6; VEGF, vascular endothelial growth factor.